Arthur Herman’s op-ed, “America Is the Sole Superpower Again,” (Jan. 15) asserts that China is “sliding into a distant second place” in the battle for economic, military and technological supremacy. While America is resurgent in many fields, we are on course to lose American dominance in perhaps the most important sector, biotechnology. America’s biotech industry supports more than 10 million jobs, $3 trillion in economic output and gives America the capability to beat back pandemics and defeat biological warfare. Not to mention delivering medical miracles in cancer, rare diseases and other areas. China’s biotech industry, fueled by extensive government support and massive industrial espionage, has grown exponentially in the past decade. China now conducts nearly as many clinical trials—and already conducts more cancer trials—as we do. The value of Chinese biotech companies has increased more than 100-fold over the past decade.

Full opinion : The value of Chinese biotechnology companies has increased more than 100-fold over the past decade.